Wegovy: Novo Nordisk's weight loss pill to be launched in Germany in September
The drug Wegovy is now also available as a tablet in the EU - first in Germany. The competing product from Eli Lilly is not yet available.
Wegovy, a weight loss pill from the Danish pharmaceutical company Novo Nordisk, will go on sale in Germany on September 1st. This makes Germany the first country in the European Union to offer the product for weight reduction. This move intensifies the competition with US rival Eli Lilly in the lucrative market for weight loss drugs, which analysts predict could reach over $100 billion per year by 2030.
The oral version of the weight loss injection Wegovy is available by prescription at pharmacies. Prices vary depending on the dosage and are comparable to those of Wegovy's pen version, with pharmacy selling prices currently ranging from €170 to €280, according to a Novo spokesperson. The pill contains the active ingredient semaglutide, which is also used in the injectable versions Wegovy for weight loss and Ozempic for diabetes.
The European Medicines Agency (EMA) recommended the drug in May, and the European Commission approved it in July.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
